authors
- Wakelee, Heather
- Braiteh, Fadi
- Cosgriff, Thomas
- Kaen, Diego
- Boyer, Michelle
- Hsu, Jessie
- Phan, See
- Novello, Silvia
- Zvirbule, Zanete
- De Braud, Filippo
- Kingsley, C Daniel
- Mekhail, Tarek
- Lowe, Thomas
- Schütte, Wolfgang
- Lena, Hervé
- Lawler, William
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2016
published in
- Clinical lung cancer Journal
has subject area
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Bevacizumab
- Carboplatin
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel
- Pemetrexed
- Prognosis
- Safety
- Survival Rate